pressmaster-shuterstock-com
Pressmaster / Shuterstock.com
6 April 2016Asia

Life sciences organisations agree antibody drug development deal

MRC Technology and the Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have agreed a partnership that will help develop new therapeutic antibodies.

IPS-CAS has experience in research into infectious diseases and generating antibodies while MRC is a medical research charity.

Together, the two bodies have created the IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development, intellectual property protection and efficient technology transfer.

The new centre was created thanks to a collaboration that was agreed by the two organisations today, April 6.

Dave Tapolczay, chief executive at MRC, said: “MRC Technology uses the potential of science to change lives. Biomedical research is flourishing in China and we are pleased to work with IPS to progress the science towards worldwide benefit.”

(Image courtesy of MRC Technology)